Point-of-Care (POC) Molecular Diagnostics Platform for a Distributed Pharmacy Network
Awarded Award Notice Posted
- Solicitation number
- 75A50122C00078
- Agency
- Office of the Assistant Secretary for Preparedness and Response Department of Health and Human Services
- Awarded
- to Diasorin Molecular, LLC
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75A50122C00078 Federal contract award
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Place of performance
- Cypress, California 90630, United States
Notice details come from SAM.gov. Updated .
About this opportunity
DiaSorin Molecular, LLC was awarded a contract by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to develop, verify and clinically validate a point-of-care molecular diagnostics platform known as the LIAISON NES, along with an initial SARS-CoV-2/Flu A&B assay. The contract value is $30,954,000 and aims to unlock the potential for disease detection and control by developing an FDA cleared and CLIA-waived point-of-care instrument for use in a distributed pharmacy network.
Notice text
In this effort, DiaSorin Molecular, aims to unlock this unrealized potential for disease detection and control by developing, verifying and clinically validating an FDA cleared and CLIA-waived POC instrument, known as the LIAISON NES, along with an initial SARS-CoV-2/Flu A&B assay.
Awarded contract 75A50122C00078 to DiaSorin Molecular LLC for 30954000.00 on 2022-09-28.
On GovTribe
Work this opportunity on GovTribe
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity